Alteogen Inc.
www.alteogen.com
Latest From Alteogen Inc.
Mylan's Aflibercept Biosimilar Gets Green Light For Trials In India
Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.
Mylan Eylea Biosimilar Gets Green Signal For Trials In India
Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
Korea Eases Stock Rules To Help Bioventures Stay Listed, Focus On R&D
South Korea continues to ease stock market listing rules to help bioventures and other innovative companies sustain growth and focus on their core R&D activities.
Company Information
- Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Immune Disorders
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
South Korea
-
South Korea
-
Pacific Rim
-
Asia
- Parent & Subsidiaries
- Alteogen Inc.
- Senior Management
-
Soon Jae Park, PhD, CEO
Moon Hwan Park, SVP, CFO
Hye-Shin Chung, PhD, CTO
Kyeong-Hoon Jeong, PhD, VP, Head R&D - Contact Info
-
Alteogen Inc.
Phone: 423848780
62 Yuseong-daero 1628, beon-gi
Yuseong-gu
Daejeon, 34054
South Korea
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice